Brainsway widens treatment scope for its Deep TMS system

Brainsway has received the CE mark for its Deep TMS (transcranial magnetic stimulation) system to treat neuropathic chronic pain in the EU and the countries in Asia and Latin America that recognise the CE mark. Neuropathic pain is the sixth indication for which Deep TMS has achieved CE mark approval, the others being for clinical depression, bi-polar disorder, schizophrenia (negative symptoms), Parkinson's diseases and post-traumatic stress disorder.

Brainsway widens treatment scope for its Deep TMS system

Brainsway has received the CE mark for its Deep TMS (transcranial magnetic stimulation) system to treat neuropathic chronic pain in the EU and the countries in Asia and Latin America that recognise the CE mark. Neuropathic pain is the sixth indication for which Deep TMS has achieved CE mark approval, the others being for clinical depression, bi-polar disorder, schizophrenia (negative symptoms), Parkinson's diseases and post-traumatic stress disorder.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.